These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 21843259

  • 1. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N, Schwarz MA, Schwarz RE.
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.
    PLoS One; 2012 Sep; 7(6):e38477. PubMed ID: 22723862
    [Abstract] [Full Text] [Related]

  • 3. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
    Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Van Damme N.
    Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
    [Abstract] [Full Text] [Related]

  • 4. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.
    BMC Cancer; 2011 Jan 12; 11():15. PubMed ID: 21226944
    [Abstract] [Full Text] [Related]

  • 5. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.
    J Exp Clin Cancer Res; 2013 Mar 06; 32(1):12. PubMed ID: 23497499
    [Abstract] [Full Text] [Related]

  • 6. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
    Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH.
    Mol Cancer Ther; 2010 Jul 06; 9(7):2068-78. PubMed ID: 20606044
    [Abstract] [Full Text] [Related]

  • 7. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.
    Oncotarget; 2015 Sep 22; 6(28):26230-41. PubMed ID: 26213847
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE.
    Cancer Lett; 2019 Sep 10; 459():41-49. PubMed ID: 31153980
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N, Yen PL, Schwarz MA, Schwarz RE.
    J Cell Biochem; 2012 Mar 10; 113(3):784-91. PubMed ID: 22020918
    [Abstract] [Full Text] [Related]

  • 10. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
    Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.
    Mol Cancer Ther; 2012 Dec 10; 11(12):2644-53. PubMed ID: 23047891
    [Abstract] [Full Text] [Related]

  • 11. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA.
    Ann Surg Oncol; 2010 May 10; 17(5):1442-52. PubMed ID: 20041350
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
    Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N.
    J Transl Med; 2018 Jul 09; 16(1):190. PubMed ID: 29986726
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.
    Eur J Cancer; 2015 Jan 09; 51(1):27-36. PubMed ID: 25459392
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 09; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.
    Cancer Chemother Pharmacol; 2005 Nov 09; 56(5):510-20. PubMed ID: 15947928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.